Thus, while DJ-V-159 on- and off-target liabilities, pharmacokinetics and ADMET studies need to be defined, the available data indicate that DJ-V-159 represents a favorable chemical probe which could be used as a starting point to develop a safe and effect drug to lower plasma glucose, increases insulin sensitivity, and reduces fat mass in T2D [49], through activation of GPRC6A. The gene discussed is INS; the disease is type 2 diabetes mellitus.